Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C7H16NO3.Cl |
Molecular Weight | 197.66 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)(C)C[C@H](O)CC(O)=O
InChI
InChIKey=JXXCENBLGFBQJM-FYZOBXCZSA-N
InChI=1S/C7H15NO3.ClH/c1-8(2,3)5-6(9)4-7(10)11;/h6,9H,4-5H2,1-3H3;1H/t6-;/m1./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C7H15NO3 |
Molecular Weight | 161.1989 |
Charge | 0 |
Count |
|
Stereochemistry | EPIMERIC |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11739607
Curator's Comment: Known to be CNS penetrant in model animals. Human data not available.
Originator
Sources: www.ncbi.nlm.nih.gov/pubmed/16857830http://adisinsight.springer.com/drugs/800003253
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P50416 Gene ID: 1374.0 Gene Symbol: CPT1A Target Organism: Homo sapiens (Human) |
|||
Target ID: P23786 Gene ID: 1376.0 Gene Symbol: CPT2 Target Organism: Homo sapiens (Human) |
|||
Target ID: P43155 Gene ID: 1384.0 Gene Symbol: CRAT Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21537157 |
|||
Target ID: O43772 Gene ID: 788.0 Gene Symbol: SLC25A20 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/21537157 |
|||
Target ID: WP408 Sources: DOI: 10.1201/b17092-12 |
|||
Target ID: CHEMBL2216739 |
|||
Target ID: WP623 Sources: DOI: 10.1201/b17092-12 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CARNITOR Approved UseCARNITOR (levocarnitine) is indicated in the treatment of primary systemic carnitine
deficiency. Launch Date1985 |
|||
Primary | Dromos Approved UseIt is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enchancement in patients with chronic congestive heart failure. |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
79.2 nmol/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7658356 |
330 mg 2 times / day multiple, oral dose: 330 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOCARNITINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
80.3 nmol/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7658356 |
2 g 2 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOCARNITINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
771.4 nmol × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7658356 |
330 mg 2 times / day multiple, oral dose: 330 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOCARNITINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
779.9 nmol × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7658356 |
2 g 2 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOCARNITINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8130774/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens. | 1987 |
|
Carnitine deficiency associated with long-term pivampicillin treatment: the effect of a replacement therapy regime. | 1992 Nov |
|
Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. | 1994 Apr |
|
Effect of L-carnitine supplementation on acute valproate intoxication. | 1996 Jul |
|
L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. | 1999 Nov |
|
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. | 2003 Jun |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats. | 2006 Aug |
|
Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. | 2006 Feb |
|
Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. | 2006 Mar |
|
High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. | 2008 Jun |
|
Increased urinary losses of carnitine and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats. | 2010 Jan |
|
The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells. | 2011 Jun 24 |
|
L-carnitine protects against nickel-induced neurotoxicity by maintaining mitochondrial function in Neuro-2a cells. | 2011 May 15 |
|
Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models. | 2012 |
|
The protection role of heat shock protein 70 (HSP-70) in the testes of cadmium-exposed rats. | 2012 |
|
L-Carnitine rescues ketamine-induced attenuated heart rate and MAPK (ERK) activity in zebrafish embryos. | 2012 Apr |
Patents
Sample Use Guides
Adults: The recommended oral dosage for adults is 990 mg two or three times a day using the 330 mg tablets, depending on clinical response. Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24005823
Human neuroblastoma or human astrocytoma cells were exposed to 100 nM (20 ug levocarnetine hydrochloride/L) to 100 uM (20 mg levocarnetine hydrochloride/L). At these concentrations levocarnetine produced significant increases in mitochondrial function.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:20:30 GMT 2023
by
admin
on
Fri Dec 15 17:20:30 GMT 2023
|
Record UNII |
J3Y5E6IKS3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000086667
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
656657
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
1426681
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
229-663-6
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
SUB01064MIG
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
DBSALT001037
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
m3119
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
J3Y5E6IKS3
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL1149
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
J3Y5E6IKS3
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
6645-46-1
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
DTXSID701014449
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY | |||
|
SUB02906MIG
Created by
admin on Fri Dec 15 17:20:30 GMT 2023 , Edited by admin on Fri Dec 15 17:20:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SALT/SOLVATE -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |